^
    2ms
    A Study of IMM-6-415 in RAS/RAF Mutant Solid Tumors (clinicaltrials.gov)
    P1/2, N=240, Recruiting, Immuneering Corporation | Not yet recruiting --> Recruiting
    Enrollment open • Metastases
    |
    IMM-6-415
    4ms
    A Study of IMM-6-415 in RAS/RAF Mutant Solid Tumors (clinicaltrials.gov)
    P1/2, N=240, Not yet recruiting, Immuneering Corporation
    New P1/2 trial • Metastases
    |
    IMM-6-415
    over1year
    Cyclic disruption of the mitogen-activated protein kinase (MAPK) pathway by the dual MEK inhibitor, IMM-6-415, enhances PD1 and CTLA4 checkpoint blockade in RAS mutant tumors (SITC 2022)
    KRAS-G12C inhibitors (sotorasib/adagrasib) have demonstrated single-agent activity in all three tumor types. Ethics Approval The protocol and any amendment(s) or procedures involving the care and use of animals in this study were reviewed and approved by the Institutional Animal Care and Use Committee (IACUC) of CrownBio prior to execution. During the study, the care and use of animals was conducted in accordance with the regulations of the Association for Assessment and Accreditation of Laboratory Animal Care (AAALAC).
    Checkpoint inhibition • PD(L)-1 Biomarker • IO biomarker
    |
    KRAS (KRAS proto-oncogene GTPase) • CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4)
    |
    KRAS mutation • KRAS G12D • RAS mutation • KRAS G12S
    |
    Lumakras (sotorasib) • Krazati (adagrasib) • IMM-6-415